Transcriptomic analysis revealed potential regulatory biomarkers and repurposable drugs for breast cancer treatment

• Published in: Cancer reports Vol. 7; no. 5; pp. e2009 - n/a
• Main Authors: Shornale Akter, Most, Uddin, Md. Helal, Atikur Rahman, Sheikh, Hossain, Md. Arju, Ashik, Md. Ashiqur Rahman, Zaman, Nurun Nesa, Faruk, Omar, Hossain, Md. Sanwar, Parvin, Anzana, Rahman, Md Habibur
• Format: Journal Article
• Language: English
• Published: United States John Wiley and Sons Inc 01.05.2024; Wiley
• Subjects: Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; biomarker; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic - drug effects; Gene Regulatory Networks; hub‐protein; Humans; in silico analysis; MicroRNAs - genetics; molecular docking; Molecular Docking Simulation; Original; Protein Interaction Maps; Signal Transduction - drug effects; Transcriptome; transcriptomics; in silico analysis; transcriptomics; breast cancer; molecular docking; biomarker; hub‐protein
• ISSN: 2573-8348; 2573-8348
• DOI: 10.1002/cnr2.2009

Breast cancer (BC) is the most widespread cancer worldwide. Over 2 million new cases of BC were identified in 2020 alone. Despite previous studies, the lack of specific biomarkers and signaling pathways implicated in BC impedes the development of potential therapeutic strategies. We employed several RNAseq datasets to extract differentially expressed genes (DEGs) based on the intersection of all datasets, followed by protein–protein interaction network construction. Using the shared DEGs, we also identified significant gene ontology (GO) and KEGG pathways to understand the signaling pathways involved in BC development. A molecular docking simulation was performed to explore potential interactions between proteins and drugs. The intersection of the four datasets resulted in 146 DEGs common, including AURKB, PLK1, TTK, UBE2C, CDCA8, KIF15, and CDC45 that are significant hub‐proteins associated with breastcancer development. These genes are crucial in complement activation, mitotic cytokinesis, aging, and cancer development. We identified key microRNAs (i.e., hsa‐miR‐16‐5p, hsa‐miR‐1‐3p, hsa‐miR‐147a, hsa‐miR‐195‐5p, and hsa‐miR‐155‐5p) that are associated with aggressive tumor behavior and poor clinical outcomes in BC. Notable transcription factors (TFs) were FOXC1, GATA2, FOXL1, ZNF24 and NR2F6. These biomarkers are involved in regulating cancer cell proliferation, invasion, and migration. Finally, molecular docking suggested Hesperidin, 2‐amino‐isoxazolopyridines, and NMS‐P715 as potential lead compounds against BC progression. We believe that these findings will provide important insight into the BC progression as well as potential biomarkers and drug candidates for therapeutic development.